#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15528	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2608	726.1	0	.	n	.	0	A69G	SNP	69	69	A	557	557	G	948	G,C	947,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15528	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2608	726.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1938	1938	T	984	T,A,G,C	978,3,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15528	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2608	726.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1672	1672	C	1019	C	1019	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26718	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4014	830.7	0	.	n	.	0	T695C	SNP	695	695	T	1234	1234	C	1004	C,T,A	1001,1,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26718	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4014	830.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2510	2510	C	895	C,G	894,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26718	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4014	830.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2584	2584	A	849	A	849	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26718	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4014	830.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3136	3136	C	957	C,T,A,G	952,1,1,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2458	folP	855	855	100.0	folP.l15.c30.ctg.1	2195	139.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1394	1396	AGC	257;259;258	A;G;C,T	257;259;257,1	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6518	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3906	208.2	1	SNP	p	S91F	1	.	.	271	273	TTC	932	934	TTC	226;226;230	T;T;C	226;226;230	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6518	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3906	208.2	1	SNP	p	D95G	1	.	.	283	285	GGC	944	946	GGC	237;238;238	G,T;G;C,T	236,1;238;237,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6518	gyrA	2751	2751	100.0	gyrA.l6.c17.ctg.1	3906	208.2	1	SNP	p	G95N	0	.	.	283	285	GGC	944	946	GGC	237;238;238	G,T;G;C,T	236,1;238;237,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	2160	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1874	143.9	0	.	p	.	0	D79N	NONSYN	235	237	GAT	836	838	AAT	247;248;247	A;A;T	247;248;247	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	2160	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1874	143.9	1	SNP	p	G45D	0	.	.	133	135	GGC	734	736	GGC	231;229;229	G;G;C	231;229;229	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1208	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1534	98.0	0	.	n	.	0	A197.	DEL	197	197	A	766	766	A	258	A	258	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3388	203.1	0	.	p	.	0	E91G	NONSYN	271	273	GAG	822	824	GGG	242;242;241	G;G,A;G	242;241,1;241	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3388	203.1	1	SNP	p	D86N	0	.	.	256	258	GAC	807	809	GAC	247;247;247	G;A;C	247;247;247	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3388	203.1	1	SNP	p	S87W	0	.	.	259	261	AGT	810	812	AGT	247;245;246	A;G,A;T	247;244,1;246	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3388	203.1	1	SNP	p	S87I	0	.	.	259	261	AGT	810	812	AGT	247;245;246	A;G,A;T	247;244,1;246	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3388	203.1	1	SNP	p	S87R	0	.	.	259	261	AGT	810	812	AGT	247;245;246	A;G,A;T	247;244,1;246	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5510	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3388	203.1	1	SNP	p	S88P	0	.	.	262	264	TCC	813	815	TCC	245;244;243	T;C;C,A	245;244;242,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4982	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3236	192.2	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1838	1840	CAC	274;274;271	C;A;C,A	274;274;270,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4982	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3236	192.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1787	1789	GGC	298;293;298	G;G;C	298;293;298	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1470	1472	GCA	249;250;249	G;C;A,G	249;250;248,1	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1473	1475	ATC	251;247;249	A;T,C;C,A	251;246,1;248,1	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1485	1487	GTG	250;252;252	G;T;G,T	250;252;251,1	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1485	1487	GTG	250;252;252	G;T;G,T	250;252;251,1	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1989	1991	ACC	247;249;248	A;C;C	247;249;248	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	T502P	0	.	.	1504	1506	ACG	2043	2045	ACG	255;254;254	A,C;C;G,A	254,1;254;253,1	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	T502V	0	.	.	1504	1506	ACG	2043	2045	ACG	255;254;254	A,C;C;G,A	254,1;254;253,1	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2166	2168	GGC	253;253;253	G;G;C	253;253;253	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2175	2177	GGC	262;264;266	G,A;G;C	260,2;264;266	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4376	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2846	192.0	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2193	2195	CTG	255;256;254	C;T;G	255;256;254	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6080	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3640	208.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1907	1909	CCG	253;253;251	C,T;C;G,C	252,1;253;250,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3058	porA	1146	1146	99.65	porA.l15.c17.ctg.1	2261	168.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	870	870	C	258	C	258	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2866	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1753	202.9	0	.	p	.	0	E48G	NONSYN	142	144	GAA	592	594	GGA	284;287;288	G;G,A;A	284;286,1;288	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2866	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1753	202.9	0	.	p	.	0	F135L	NONSYN	403	405	TTT	853	855	CTT	231;232;235	C,A;T;T	230,1;232;235	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2866	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1753	202.9	0	.	p	.	0	R143G	NONSYN	427	429	AGA	877	879	GGA	230;231;233	G,C,A;G,C;A	228,1,1;230,1;233	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2866	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1753	202.9	0	.	p	.	0	D171G	NONSYN	511	513	GAT	961	963	GGT	265;264;263	G;G,A;T,C	265;263,1;262,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2866	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1753	202.9	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1015	1017	AGC	273;273;272	A;G;C	273;273;272	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2866	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1753	202.9	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1081	1081	T	232	T	232	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2866	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1753	202.9	1	SNP	p	G120K	0	.	.	358	360	GGT	808	810	GGT	245;246;245	G,A,T;G;T	243,1,1;246;245	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2866	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1753	202.9	1	SNP	p	A121D	0	.	.	361	363	GCC	811	813	GCC	241;245;243	G;C;C	241;245;243	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2866	porB1b	1035	1035	95.82	porB1b.l15.c17.ctg.1	1753	202.9	1	SNP	p	A121N	0	.	.	361	363	GCC	811	813	GCC	241;245;243	G;C;C	241;245;243	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10178	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5354	237.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2232	2234	CAT	262;260;257	C;A;T,C	262;260;256,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1438	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1376	129.9	1	SNP	p	V57M	1	.	.	169	171	ATG	726	728	ATG	258;258;260	A;T,C;G	258;257,1;260	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
